A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Clinical trial NCT03499899 · COMPLETED
Trial details
- NCT number
- NCT03499899
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2020-02-27
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.